Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer

Recruiting in Palo Alto (17 mi)

Overseen byGrace Dy

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Roswell Park Cancer Institute

No Placebo Group

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?

This trial is testing nimotuzumab and nivolumab, two drugs that help the immune system fight cancer. It targets patients with advanced non-small cell lung cancer that has spread and is hard to treat. These drugs work by helping the immune system recognize and attack cancer cells. Nivolumab is an immune checkpoint inhibitor that has shown promise in treating various cancers, including non-small cell lung cancer (NSCLC).

Eligibility Criteria

Inclusion Criteria

You are expected to live for at least 3 more months.

Patients with pathologically confirmed non-small cell lung cancer

Have measurable disease per RECIST 1.1 criteria present

See 14 more

Exclusion Criteria

You are allergic to the ingredients in the study drugs or similar medicines.

You have a heart problem that is not under control or you have trouble with your heart's function.

You have a history of severe chest pain that cannot be controlled with medication.

See 15 more

Treatment Details

Interventions

Nimotuzumab (Monoclonal Antibodies)
Nivolumab (Checkpoint Inhibitor)

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Treatment (nivolumab, nimotuzumab)Experimental Treatment3 Interventions

Patients receive nivolumab IV over 60 minutes and nimotuzumab IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.